METASTATIC SOLID TUMOR

This study tests an experimental drug called TransCon IL-2 β/γ, which is designed to boost the immune system's ability to fight advanced solid tumors. About 320 adults with cancers like ovarian, melanoma, lung, or cervical cancer will receive the drug alone or combined with other…

This early-phase study tests a new oral drug, MOMA-313, alone or with another drug (olaparib) in people with advanced solid tumors that have a specific DNA repair problem (HR deficiency). The main goals are to check safety, find the best dose, and see if the drug shrinks tumors. …

This early-phase study tests a new drug called LY4066434 in people with advanced solid tumors that have certain KRAS mutations. The main goal is to see if the drug is safe and tolerable when given alone or with other treatments. About 750 participants with pancreatic, lung, or co…

This early-phase study tests a new drug called DS-1055a in about 40 adults with advanced solid tumors (like head and neck, stomach, or lung cancer) that have not responded to standard treatments. The main goal is to check the drug's safety and find the right dose. Participants re…

This study tests a new drug called LP-184 in people with advanced solid tumors (like certain breast, lung, or pancreatic cancers) that have stopped responding to standard treatments. The main goals are to find a safe dose and see if the drug can shrink tumors. About 64 participan…

This study tests a drug called sacituzumab govitecan in 227 people whose solid tumors have spread to other parts of the body. The goal is to see if the drug can shrink or control the cancer. Participants must have already tried standard treatments like chemotherapy or immunothera…

This early-phase study tests a new drug called LY4101174 in people with advanced or metastatic solid tumors, including bladder, breast, lung, and other cancers. The goal is to find a safe and effective dose and see if the drug can shrink tumors. About 490 participants will take p…

This early-phase study tests a new drug called WTX-124, given alone or with another drug (pembrolizumab), in 150 people with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety and find the right dose, while also looking at whe…

This early-stage study tests a new treatment called M-CENK, made from a patient's own immune cells, combined with a drug called N-803. It is for people with advanced solid tumors that have not responded to other treatments. The main goal is to check if the treatment is safe and t…

This study looks back at medical records of 72 American Indian adults with cancers like lung, melanoma, and kidney who received immunotherapy. Researchers compare their outcomes, such as cancer progression and side effects, to those of White patients. The goal is to spot any diff…